Skip to main content
Premium Trial:

Request an Annual Quote

Quark Biotech Gets US Patent for Microarray-Based Gene ID Technique

NEW YORK, July 29 - The genomics-based drug discovery company Quark Biotech was granted a U.S. patent for a technique to identify genes that encode for membranal and secreted proteins, the company said today.

Quark's technique identifies cDNAs and genes of interest by using template RNA extracted from membrane-bound and free polysomes to create probes. The method then uses microarrays to compare the relative abundance of different RNA segments.

According to Quark, the technique allows researchers to identify promising drug targets without first needing to know gene sequences.These proteins are of pharmaceutical interest because they are often involved in molecular transport, cell recognition and cell-to-cell communication, and are biologically accessible.


The patent was granted by the U.S. Patent and Trade Office on June 11.

Quark Biotech, based in Cleveland, is a privately held drug development company with research labs in Pleasanton, Calif. and Ness-Ziona, Israel. It bought Incyte's microarray businessearlier this month.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.